Skip to main content

Advertisement

SpringerLink
Log in

Thyroid Hormones Imbalances and Risk of Colorectal Cancer: a Meta-analysis

  • Review Article
  • Published:
Journal of Gastrointestinal Cancer Aims and scope Submit manuscript

Abstract

Purpose

No conclusive information is available about the association between hypothyroidism or hyperthyroidism and risk of colorectal cancer (CRC). We therefore aimed to summarize the findings of observational studies on the relation between hypothyroidism or hyperthyroidism and risk of CRC.

Methods

A literature search was conducted using relevant keywords in online databases for appropriate publications through July 2023. Random effects model was used to calculate combined effect sizes (ESs) and 95% confidence intervals (CIs) to investigate relationship between hypothyroidism or hyperthyroidism and CRC risk.

Results

Totally, we included 13 studies in the current systematic review and meta-analysis, with a total sample size of 33,557,450 individuals and 25,363 cases of CRC. Pooling 13 effect sizes revealed no significant association between hypothyroidism and risk of CRC (combined effect size: 1.13, 95% CI 0.87–1.48, P = 0.343). There was also no significant association between hyperthyroidism and risk of CRC (combined effect size: 1.09, 95% CI 0.75–1.57, P = 0.638). Additionally, there were significant associations between hypothyroidism and risk of CRC in the Far Eastern studies, between hyperthyroidism and risk of CRC in the Middle East, along with small sample size studies.

Conclusions

This meta-analysis did not reveal any association between hypothyroidism or hyperthyroidism and risk of CRC.

Trial Registration

PROSPERO CRD42022331089.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

Availability of Data and Materials

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Abbreviations

CRC:

Colorectal cancer

ESs:

Effect sizes

CIs:

Confidence intervals

THs:

Thyroid hormones

TSH:

Thyroid stimulating hormone

T4:

Tetraiodothyronine

T3:

Triiodothyronine

TRα:

Thyroid hormone receptors alpha

TRβ:

Thyroid hormone receptors beta

TREs:

Thyroid hormone response elements

PRISMA:

Preferred Reporting Items for Systematic Review and Meta-Analysis

RR:

Relative risk

HR:

Hazard ratio

OR:

Odds ratio

NOS:

Newcastle-Ottawa Scale

PI3K:

Phosphatidyl inositol 3-kinase

HIF1α:

Hypoxia-inducible factor-1α

DIO3:

Deiodinase type III

DIO2:

Deiodinase type II

rT3:

Reverse T3

NTIS:

Non-thyroidal illness syndrome

References

  1. Ortiga-Carvalho TM, Chiamolera MI, Pazos-Moura CC, Wondisford FE. Hypothalamus-pituitary-thyroid axis. Compr Physiol. 2011;6(3):1387–428.

    Google Scholar 

  2. Piekiełko-Witkowska A, Nauman A. Iodothyronine deiodinases and cancer. J Endocrinol Invest. 2011;34(9):716–28.

    PubMed  Google Scholar 

  3. Davis PJ, Goglia F, Leonard JL. Nongenomic actions of thyroid hormone. Nat Rev Endocrinol. 2016;12(2):111–21.

    Article  CAS  PubMed  Google Scholar 

  4. Taylor PN, Albrecht D, Scholz A, Gutierrez-Buey G, Lazarus JH, Dayan CM, Okosieme OE. Global epidemiology of hyperthyroidism and hypothyroidism. Nat Rev Endocrinol. 2018;14(5):301–16.

    Article  PubMed  Google Scholar 

  5. Huang CH, Wei JC, Chien TC, Kuo CW, Lin SH, Su YC, Hsu CY, Chiou JY, Yeh MH. Risk of breast cancer in females with hypothyroidism: a nationwide, population-based, cohort study. Endocr Pract. 2021;27(4):298–305.

    Article  PubMed  Google Scholar 

  6. Kirkegård J, Farkas DK, Jørgensen JOL, Cronin-Fenton D. Hyper- and hypothyroidism and gastrointestinal cancer risk: a Danish nationwide cohort study. Endocr Connect. 2018;7(11):1129–35.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Søgaard M, Farkas DK, Ehrenstein V, Jørgensen JO, Dekkers OM, Sørensen HT. Hypothyroidism and hyperthyroidism and breast cancer risk: a nationwide cohort study. Eur J Endocrinol. 2016;174(4):409–14.

    Article  PubMed  Google Scholar 

  8. Yeh NC, Chou CW, Weng SF, Yang CY, Yen FC, Lee SY, Wang JJ, Tien KJ. Hyperthyroidism and thyroid cancer risk: a population-based cohort study. Exp Clin Endocrinol Diabetes. 2013;121(7):402–6.

    Article  CAS  PubMed  Google Scholar 

  9. L’Heureux A, Wieland DR, Weng C-H, Chen Y-H, Lin C-H, Lin T-H, Weng C-H. Association between thyroid disorders and colorectal cancer risk in adult patients in Taiwan. JAMA Netw Open. 2019;2(5):e193755–e193755.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Wolf AM, Fontham ET, Church TR, Flowers CR, Guerra CE, LaMonte SJ, Etzioni R, McKenna MT, Oeffinger KC, Shih YCT. Colorectal cancer screening for average‐risk adults: 2018 guideline update from the American Cancer Society. CA: Cancer J Clin. 2018;68(4):250–281.

  11. Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017;66(4):683–91.

    Article  PubMed  Google Scholar 

  12. Rennert G, Rennert HS, Pinchev M, Gruber SB. A case-control study of levothyroxine and the risk of colorectal cancer. J Natl Cancer Inst. 2010;102(8):568–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Chen YK, Lin CL, Cheng FT, Sung FC, Kao CH. Cancer risk in patients with Hashimoto’s thyroiditis: a nationwide cohort study. Br J Cancer. 2013;109(9):2496–501.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev. 2021;10(1):89.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–5.

    Article  PubMed  Google Scholar 

  16. DerSimonian R, Laird N. Meta-analysis in clinical trials revisited. Contemp Clin Trials. 2015;45(Pt A):139–45.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Chandler J, Cumpston M, Li T. Cochrane handbook for systematic reviews of interventions.

  18. van Enst WA, Ochodo E, Scholten RJ, Hooft L, Leeflang MM. Investigation of publication bias in meta-analyses of diagnostic test accuracy: a meta-epidemiological study. BMC Med Res Methodol. 2014;14(1):1–11.

    Google Scholar 

  19. Mansoor E, Chouhan V, Abou Saleh M, Sheriff ZM, Cooper GS. 330 increased risk of colorectal cancer in individuals with hypothyroidism and hyperthyroidism: results from a population-based national study. Offic J Am Coll Gastroenterol | ACG. 2019;114:S194.

  20. Kirkegård J, Farkas DK, Jørgensen JOL, Cronin-Fenton DP. Hyperthyroidism or hypothyroidism and gastrointestinal cancer risk: a Danish nationwide cohort study. Endocr Connect. 2018;7(11):1129–35.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Chan YX, Knuiman MW, Divitini ML, Brown SJ, Walsh J, Yeap BB. Lower TSH and higher free thyroxine predict incidence of prostate but not breast, colorectal or lung cancer. Eur J Endocrinol. 2017;177(4):297–308.

    Article  CAS  PubMed  Google Scholar 

  22. Chan YX, Alfonso H, Chubb SAP, Fegan PG, Hankey GJ, Golledge J, Flicker L, Yeap BB. Higher thyrotropin concentration is associated with increased incidence of colorectal cancer in older men. Clin Endocrinol. 2017;86(2):278–85.

    Article  CAS  Google Scholar 

  23. Mu G, Mu X, Xing H, Xu R, Sun G, Dong C, Pan Q, Xu C. Subclinical hypothyroidism as an independent risk factor for colorectal neoplasm. Clin Res Hepatol Gastroenterol. 2015;39(2):261–6.

    Article  PubMed  Google Scholar 

  24. Boursi B, Haynes K, Mamtani R, Yang Y-X. Thyroid dysfunction, thyroid hormone replacement and colorectal cancer risk. J Natl Cancer Inst. 2015;107(6):djv084.

  25. Chen Y-K, Lin C-L, Chang Y-J. Cheng FT-F, Peng C-L, Sung F-C, Cheng Y-H, Kao C-H. Cancer risk in patients with Graves’ disease: a nationwide cohort study. Thyroid. 2013;23(7):879–84.

  26. Hellevik AI, Åsvold BO, Bjøro T, Romundstad PR, Nilsen TIL, Vatten LJ. Thyroid function and cancer risk: a prospective population study. Cancer Epidemiology and Prevention Biomarkers. 2009;18(2):570–4.

    Article  CAS  Google Scholar 

  27. Kuiper JG, Fenneman AC, van der Spek AH, Rampanelli E, Nieuwdorp M, van Herk-Sukel MP, Lemmens VE, Kuipers EJ, Herings RM, Fliers E. Levothyroxine use and the risk of colorectal cancer: a large population-based case–control study. Endocr Connect. 2022;11(1).

  28. Wu CC, Islam MM, Nguyen PA, Poly TN, Wang CH, Iqbal U, Li YCJ, Yang HC. Risk of cancer in long-term levothyroxine users: retrospective population-based study. Cancer Sci. 2021;112(6):2533.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Rennert G, Rennert HS, Pinchev M, Gruber SB. A case–control study of levothyroxine and the risk of colorectal cancer. J Natl Cancer Inst. 2010;102(8):568–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Kuiper JG, Fenneman AC, van der Spek AH, Rampanelli E, Nieuwdorp M, van Herk-Sukel MPP, Lemmens V, Kuipers EJ, Herings RMC, Fliers E. Levothyroxine use and the risk of colorectal cancer: a large population-based case-control study. Endocr Connect. 2022;11(1).

  31. Chen Y-K, Lin C-L, Chang Y-J. Cheng FT-F, Peng C-L, Sung F-C, Cheng Y-H, Kao C-H. Cancer risk in patients with Graves’ disease: a nationwide cohort study. Thyroid Offic J Am Thyroid Assoc. 2013;23(7):879–84.

  32. Boursi B, Haynes K, Mamtani R, Yang YX. Thyroid dysfunction, thyroid hormone replacement and colorectal cancer risk. J Natl Cancer Inst. 2015;107(6).

  33. L’Heureux A, Wieland DR, Weng CH, Chen YH, Lin CH, Lin TH, Weng CH. Association between thyroid disorders and colorectal cancer risk in adult patients in Taiwan. JAMA Netw Open. 2019;2(5).

  34. Kirkegård J, Farkas DK, Jørgensen JOL, Fenton DPC. Hyperthyroidism or hypothyroidism and gastrointestinal cancer risk: a Danish nationwide cohort study. Endocr Connect. 2018;7(11):1129–35.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Alikhan M, Mansoor E, Panhwar MS, Abou Saleh M, Chouhan V, Sheriff MZ, Cooper GS. Increased risk of colorectal cancer in individuals with hypothyroidism and hyperthyroidism: results from a population-based national study. Gastroenterology. 2020;158(6):S499–500.

    Article  Google Scholar 

  36. Krashin E, Piekiełko-Witkowska A, Ellis M, Ashur-Fabian O. Thyroid hormones and cancer: a comprehensive review of preclinical and clinical studies. Front Endocrinol. 2019;10:59.

    Article  Google Scholar 

  37. Rawla P, Sunkara T, Barsouk A. Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors. Przeglad gastroenterologiczny. 2019;14(2):89–103.

    CAS  PubMed  PubMed Central  Google Scholar 

  38. Rostkowska O, Spychalski P, Dobrzycka M, Wilczyński M, Łachiński AJ, Obołończyk Ł, Sworczak K, Kobiela J. Effects of thyroid hormone imbalance on colorectal cancer carcinogenesis and risk - a systematic review. Endokrynol Pol. 2019;70(2):190–7.

    Article  CAS  PubMed  Google Scholar 

  39. Lars CM, Dagmar F. Thyroid hormone, thyroid hormone receptors, and cancer: a clinical perspective. Endocr Relat Cancer. 2013;20(2):R19–29.

    Article  Google Scholar 

  40. Khan SR, Chaker L, Ruiter R, Aerts JGJV, Hofman A, Dehghan A, Franco OH, Stricker BHC, Peeters RP. Thyroid function and cancer risk: the Rotterdam study. J Clin Endocrinol Metab. 2016;101(12):5030–6.

    Article  CAS  PubMed  Google Scholar 

  41. Boursi B, Haynes K, Mamtani R, Yang Y-X. Thyroid dysfunction, thyroid hormone replacement and colorectal cancer risk. JNCI: J Natl Cancer Inst. 2015;107(6).

  42. Liu Y-C, Yeh C-T, Lin K-H. Molecular functions of thyroid hormone signaling in regulation of cancer progression and anti-apoptosis. Int J Mol Sci. 2019;20(20):4986.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Zhu L, Tian G, Yang Q, De G, Zhang Z, Wang Y, Nie H, Zhang Y, Yang X, Li J. Thyroid hormone receptor β1 suppresses proliferation and migration by inhibiting PI3K/Akt signaling in human colorectal cancer cells. Oncol Rep. 2016;36(3):1419–26.

    Article  CAS  PubMed  Google Scholar 

  44. Brown AR, Simmen RCM, Simmen FA. The role of thyroid hormone signaling in the prevention of digestive system cancers. Int J Mol Sci. 2013;14(8):16240–57.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Dentice M, Luongo C, Ambrosio R, Sibilio A, Casillo A, Iaccarino A, Troncone G, Fenzi G, Larsen PR, Salvatore D. β-catenin regulates deiodinase levels and thyroid hormone signaling in colon cancer cells. Gastroenterology. 2012;143(4):1037–47.

    Article  CAS  PubMed  Google Scholar 

  46. Shimi G, Zand H, Pourvali K, Ghorbani A. Colorectal cancer causes alteration of thyroid hormone profile in newly diagnosed patients. Expert Rev Endocrinol Metab. 2021;16(5):259–62.

    Article  CAS  PubMed  Google Scholar 

  47. Deligiorgi MV, Trafalis DT. The intriguing thyroid hormones-lung cancer association as exemplification of the thyroid hormones-cancer association: three decades of evolving research. Int J Mol Sci. 2021;23(1):436.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Pasqualetti G, Schirripa M, Dochy E, Fassan M, Ziranu P, Puzzoni M, Scartozzi M, Alberti G, Lonardi S, Zagonel V, et al. Thyroid hormones ratio is a major prognostic marker in advanced metastatic colorectal cancer: results from the phase III randomised CORRECT trial. Eur J Cancer (Oxford, England : 1990). 2020;133:66–73.

  49. Gómez-Izquierdo J, Filion KB, Boivin J-F, Azoulay L, Pollak M, Yu OHY. Subclinical hypothyroidism and the risk of cancer incidence and cancer mortality: a systematic review. BMC Endocr Disord. 2020;20(1):83.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

Not applicable.

Funding

Not applicable.

Author information

Author notes

  1. Omid Asbaghi and Ghazaleh Shimi contributed equally to this work.

Authors and Affiliations

  1. Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

    Omid Asbaghi & Sayed Hossein Davoodi

  2. Department of Cellular and Molecular Nutrition, Faculty of Nutrition Science and Food Technology, National Nutrition and Food Technology Research Institute, Shahid Beheshti University of Medical Sciences, 1981619573, Tehran, Iran

    Ghazaleh Shimi, Katayoun Pourvali, Ghazaleh Eslamian & Hamid Zand

  3. National Nutrition and Food Technology Research Institute, Faculty of Nutrition Sciences and Food Technology, Shahid Beheshti University of Medical Sciences, Tehran, Iran

    Sayed Hossein Davoodi

Authors
  1. Omid Asbaghi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ghazaleh Shimi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sayed Hossein Davoodi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Katayoun Pourvali
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ghazaleh Eslamian
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hamid Zand
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Conceptualization: O.A. and G.S; Methodology: O.A. and G.S; Formal analysis and investigation: O.A.; Writing original draft preparation: O.A. and G.S; Writing review and editing: K.P. and G.E.; Supervision: H.Z. and S.H.D. All authors have approved the submitted draft.

Corresponding author

Correspondence to Hamid Zand.

Ethics declarations

Ethics Approval and Consent to Participate

Not applicable.

Consent for Publication

Not applicable.

Conflict of Interest

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 13 KB)

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Asbaghi, O., Shimi, G., Davoodi, S.H. et al. Thyroid Hormones Imbalances and Risk of Colorectal Cancer: a Meta-analysis. J Gastrointest Canc 55, 105–117 (2024). https://doi.org/10.1007/s12029-023-00979-4

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12029-023-00979-4

Keywords

Search

Navigation